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Scleroderma in particular has been most commonly associated with lung cancer, hematological malignancies, and non-melanoma skin cancers. 2 Patients with scleroderma have an estimated overall 1.5 to 2.4-fold increase in risk of developing a malignancy. 3 Alternatively, connective tissue disorders may manifest as rheumatological paraneoplastic syndromes. Although the mechanism remains unclear, tumors may induce such disorders through the secretion of hormones, cytokines, peptides, and other mediators. 4 These disorders may manifest at the time of malignancy diagnosis, or appear several years before or after the diagnosis. 5 Rheumatic manifestations in scleroderma patients have improved with treatment for a co-existing malignancy, while relapse has led to symptom recurrence. 5 We describe a patient with limited scleroderma whose rapid disease progression coincided with the discovery of a renal tumor.
Case Presentation
A female patient, aged 75 years, presented with a 3-month history of difficulty grasping objects, unsteadiness on her feet, progressive shortness of breath, dryness of the eyes and mouth, and a 35-pound weight loss. She described a 10-year history of gastroesophageal reflux disease and
Raynaud's phenomenon with progressive skin tightening in her hands. Medical treatment was started one month before surgery. The patient received three pulses of intravenous methylprednisolone before being placed on modest doses of oral prednisone. She also received two doses of rituximab; the first was administered soon after the first pulse of methylprednisolone, and the second was administered after the surgery. After starting medical therapy, she experienced clinical improvement in her sclerodactyly, polyarthritis, and dyspnea.
Her renal function also showed some improvement, and with medical therapy, her creatinine decreased from 1.2 mg/dL to 1.0 mg/dL and estimated glomerular filtration rate (eGFR) increased from 44 mL/min/1.73 m 2 to 57 mL/min/1.73 m 2 , suggesting only a modest response to treatment. After the left partial nephrectomy, the creatinine further decreased to 0.9 mg/dL with the eGFR increasing to 61 mL/min/1.73 m 2 . The patient's liver enzymes normalized CRP decreased to 0.4 mg/dL, white blood cell count decreased to 13.5 x 10 3 /µL, and the hemoglobin increased to 12.1 g/dL. Half a year later, the patient reported increased range of motion in her hands and marked improvement in the dryness of her eyes and mouth. She also reported better sensation in her fingers and toes, which was accompanied by a return of pinprick and vibration sensation on neurological exam. Her synovitis had resolved, and the urinalysis was devoid of hematuria.
Discussion
Our patient's disease prior to presentation is consistent with limited scleroderma, also known as CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias). On presentation, she exhibited rapid disease progression with development of subacute pulmonary fibrosis, polyarthritis, a sensorimotor neuropathy, and a pauci-immune crescentic glomerulonephritis. Pulmonary fibrosis commonly occurs as a late complication in patients with limited scleroderma, and is associated with the development of pulmonary hypertension. 7 In contrast, pauci-immune crescentic glomerulonephritis is rare in scleroderma.
When it does occur, the anti-neutrophil cytoplasmic antibody specificity is usually directed against myeloperoxidase. 8 The vasculitis typically affects the small vessels, and can be observed in up to one third of tissue biopsies. 9 Malignancy has been suggested as a trigger for the development of ANCA-positive vasculitis, which has been seen in association with urinary tract cancers. 10 Our patient developed a sensorimotor neuropathy, which is commonly associated with scleroderma. Damage to the peripheral nerves typically involves a combination of axonal demyelination and lesions affecting the nerve fibers, causing a mixed neuropathy. 11 Damage occurs as a result of ischemia secondary to vasculitis of the vasa nervorum, and also from humoral and cell-mediated autoimmune destruction. 11 Renal cell carcinomas can also produce peripheral neuropathies through a paraneoplastic mechanism. However, this is unlikely in our patient since peripheral neuropathies associated with renal cell carcinoma tend to impact either the sensory or motor nervous system.
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Based on the sequence of events, the patient likely suffered from limited scleroderma that went undiagnosed for several years. With the new finding of a renal tumor, the rapid development of new symptoms in our patient would suggest paraneoplastic stimulation by the renal cell carcinoma causing a progression of her disease. The latter is suggested by our patient's serology, since the presence of SSA antibodies may be a marker for malignancy in the context of certain autoimmune phenomena. 13 This is further supported by the presence of elevated liver transaminases, a known paraneoplastic manifestation of renal cell carcinoma called Stauffer's syndrome. 12 Despite these clues, it is important to consider that the patient's new symptoms could have also occurred as a natural progression of the limited scleroderma with the renal tumor being an incidental finding. Unfortunately, we can only speculate regarding pathogenesis, since primary and paraneoplastic presentations of connective tissue disorders are indistinguishable. 5 Although the initial discovery of our patient's connective tissue disorder and malignancy occurred in the inpatient setting, treatment was initiated as an outpatient. Unfortunately, the partial nephrectomy was scheduled one month after discharge. Due to the uncertainty of the disease process, the decision was made to begin medical therapy before surgery to prevent 
